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ABSTRACT
Anti-epidermal growth factor receptor therapy with the monoclonal antibodies 
cetuximab and panitumumab is the main targeted treatment to combine with standard 
chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the 
benefit of the addition of these agents for patients without mutations in the EGFR 
pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, 
PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification 
have already been identified to select responders to anti-EGFR agents. Among these 
alterations KRAS and NRAS mutations are currently recognized as the best predictive 
factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor 
DNA, is an innovative method to study both primary and acquired resistance to anti-
EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to 
enable the identification of a wide set of gene mutations related to resistance.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes 
of cancer-related death. Around half of CRC patients 
develop distant metastases, which can be detected early at 
diagnosis or at a later stage. Despite the development of 
different treatment options, the outcome for patients with 
unresectable metastatic lesions is still unfavorable and 
the metastatic spread to the liver is the major contributor 
to mortality in CRC. New drugs such as oxaliplatin, 
irinotecan, bevacizumab, aflibercept, cetuximab, 
panitumumab and regorafenib have led to a significant 
improvement in median survival from 6-7 months to 
24-30 months in patients with unresectable metastatic 
CRC (mCRC), also improving quality of life [1, 2]. New 
biological agents mainly target two different pathways: 
tumor growth mediated by proangiogenic factors, and 
Epidermal Growth Factor Receptor (EGFR)-triggered 
cell proliferation [3]. Predictive biomarkers with clinical 
relevance for sensitivity to anti-angiogenic drugs have not 
yet been defined [4]. Conversely, anti-EGFR monoclonal 
antibodies (moAbs) are effective in those patients whose 
tumors do not have specific biomarkers, such as KRAS, 
NRAS, BRAF, and PIK3CA gene mutations [5, 6]. The 
establishment of the predictive role of these and other 
biomarkers has allowed the identification of patients 
suitable for anti-angiogenic therapy and spares others from 
unnecessary anti-EGFR therapy [7, 8].
The majority of these biomarkers are still under 
investigation to define the mechanisms of primary 
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resistance. In the meantime some preclinical studies are 
evaluating the development of acquired resistance to anti-
EGFR moAbs.
The new methodology of liquid biopsy has added 
new perspectives to the standard biomarker evaluation 
in tissue biopsy. The different sensitivity of various 
techniques is the main parameter to reach proper clinical 
validation. This review aims to highlight the recent status 
of translational research on mechanisms and predictive 
factors of intrinsic and acquired resistance.
THE IMPORTANCE OF DETECTION 
METHODS
In recent years, new targeted therapies have been 
exploited in the treatment of mCRC patients. Cetuximab 
and Panitumumab are monoclonal antibodies that bind to 
EGFR, causing anti-tumor activity [9-12]. Nevertheless, 
these drugs show a clinical benefit in only a small 
percentage of cancer patients and this is mainly due to 
molecular alterations in EGFR pathway effectors [13]. It 
has been demonstrated in several randomized controlled 
trials that somatic single-nucleotide point mutations 
in codons 12 and 13 of the KRAS gene determine a 
constitutive activation of the MAPK pathway, thus leading 
to anti-EGFR treatment resistance. KRAS mutations are 
negative predictive markers and patient selection for anti-
EGFR treatment is dependent on KRAS mutational status 
[12]. Recently it has been proved that the mutational status 
of other RAS family genes (specifically NRAS), but also 
KRAS mutations outside exon 2, are negative predictors 
for response to anti-EGFR drugs [14]. Furthermore, a 
recent meta-analysis demonstrated that approximately 
20% of KRAS exon 2 wild-type tumors harbor one of the 
new RAS mutations. Thus CRC patients without any RAS 
mutations (either KRAS exon 2 or new RAS mutations) 
significantly benefit from anti-EGFR treatment compared 
with tumors with any of the new RAS mutations [15]. 
Given that patients diagnosed with mCRC are 
routinely tested for RAS mutational status, it is known 
that 35-50% of CRC harbor RAS mutations [16]. RAS 
testing has become mandatory for an appropriate 
treatment decision. There are several methodologies for 
RAS mutation detection with different advantages and 
disadvantages. 
Despite the promising advances that have been 
made so far there is still a lack of a clinically-proven 
circulating biomarker that can be used to guide patient 
management [17]. To date, the follow-up of mCRC 
patients has mainly been based on imaging techniques 
(CT scan, PET, MRI etc…) and serum-based protein 
biomarkers such as the carcinoma antigen-125 (CA-
125) and the carcinoembryonic antigen (CEA). The 
main limitation in using these biomarkers is that they are 
detectable also in healthy individuals (albeit at a lower 
concentration) and thus they do not perfectly fit one of 
the most important features of a circulating biomarker, 
i.e. to be highly specific for a pathological condition. The 
Cancer Genome Atlas (TCGA) is an international database 
that collects genomic information from cancer genome 
sequencing and it is contributing to expand knowledge 
about the molecular biology of several tumor types. It is 
noteworthy that almost every tumor type harbors somatic 
genetic alterations and that these somatic alterations arise 
prevalently in cancer cells. Therefore somatic alterations 
are 100% specific for cancer and can be used as specific 
biomarkers from a biological perspective [18]. Until some 
time ago the only source of tumor DNA was represented 
by a tumor tissue sample, but nowadays we know that 
DNA, from both healthy and cancer cells, is also diffused 
into the circulation. Therefore a relatively non-invasive 
source of tumor DNA is represented by plasma or serum. 
Cell-free circulating tumor DNA (ctDNA) is a promising 
candidate biomarker for the detection, monitoring and 
prognostic prediction of malignant tumors and can be 
defined also as a liquid biopsy [19, 20]. A liquid biopsy is 
a biomarker that can be easily isolated from blood and, as 
well as a tissue biopsy, is representative of the tissue from 
which it is spread [21].
Tissue DNA vs circulating DNA
DNA mutational analysis on formalin-fixed paraffin 
embedded (FFPE) tissue is nowadays a routine practice in 
medical oncology. The identification of a specific tumor 
genotype is mandatory for treatment decision and RAS 
testing is always requested for mCRC patients.
Currently the evaluation of RAS mutational status 
from FFPE is the only procedure recognized and accepted 
in clinical practice. In the near future, we might witness 
the introduction of ctDNA testing as a precise, efficient 
and non-invasive technique for mutation detection both at 
diagnosis and during subsequent follow-up.
Circulating free DNA may also have a diagnostic 
value. Cell-free DNA (cfDNA) is released from both 
healthy and cancer cells. Healthy cells are normally 
destroyed through a regulated and orderly process; in 
apoptotic cells DNA is uniformly truncated into 185- to 
200-bp fragments. CfDNA released by necrotic cells, 
and hence mainly tumor cells, varies in length. Thus 
a preponderance of longer DNA fragments could be a 
marker for tumor detection [22, 23]. The DNA integrity 
index can be calculated as the ratio of longer to shorter 
fragments. In 2006 Umetani et al. analyzed the DNA 
Integrity Index (DII) in colorectal or periampullary cancer 
[24]. The aim of the study was to evaluate ALU-repeats 
fragments of different lengths by means of quantitative 
PCR (qPCR). The short fragments (115bp) also represent 
the total amount of circulating DNA whereas the long 
fragments (247bp) are assumed to derive from necrotic 
cells. The ratio of ALU247/ALU115 is defined as the 
DII and was found to be significantly increased even in 
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localized CRC and periampullary cancers. Recently T.B. 
Hao et al. also demonstrated that DII evaluation might 
be a useful biomarker for the diagnosis and prognostic 
prediction of colorectal cancer [25] and the combination 
with CEA could improve the diagnostic efficiency for 
CRC. CfDNA concentration and DII are interesting 
tools that might be valuable in the early complementary 
diagnosis and monitoring of progression and prognosis of 
CRC.
As previously mentioned, RAS testing in FFPE 
tissue is considered a routine practice but it is nonetheless 
challenging, mainly due to the DNA degradation that 
occurs during fixation procedures. The analysis of FFPE 
material gives a snapshot of the tumor in a specific 
moment but it does not provide any information about 
disease evolution or heterogeneity. ctDNA analysis offers 
the challenging opportunity to follow tumor molecular 
modifications over time and space. We can repeatedly 
assess ctDNA at different time-points during treatment. 
For metastatic patients, with multiple lesions, ctDNA is 
composed of a mixture of DNA released from the different 
lesions, and thus allows evaluation beyond the tumour 
tissue heterogeneity, even though we might not be able to 
detect exactly which lesions harbor a specific mutation.
It is known that KRAS mutations confer primary 
resistance to anti-EGFR treatment, but it is still not clear 
whether mutations in this gene are acquired after treatment 
or are pre-existing at low levels in tumors with ostensibly 
wild type KRAS genes. Diaz et al. in 2012 determined 
whether mutant KRAS DNA could be detected in the 
circulation of patients receiving monotherapy with anti-
EGFR drugs [26]. 38% of patients, whose tumors were 
initially KRAS wild type, developed detectable mutations 
of KRAS in their ctDNA. The mutations might presumably 
arise in a small subclone population of cancer cells and 
then expand under the pressure of the EGFR blockade. 
Figure 1: Proposed flow-chart of RAS analysis with Melting curve test. After the diagnosis of metastatic colorectal cancer, 
RAS analysis is always requested before treatment initiation. Melt-curve analysis allows a quick screening of all RAS mutations. If the 
melting curve has a normal profile the sample can be reported as wild type and thus the patient can be selected for the specific targeted 
treatments. If the melting curve is altered it is mandatory to proceed with other tests (either Sanger sequencing or pyrosequencing), in order 
to identify the mutation. If a mutation is detected the patient is subjected to standard chemotherapy (CT); in the opposite case (RAS wild 
type) patients are selected for anti-EGFR treatment.
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Furthermore, Bettegowda et al. demonstrated for the 
first time that NRAS codon 61 mutations are involved in 
acquired resistance [17].
Low- vs high-sensitivity techniques
Sanger sequencing was previously the gold 
standard methodology to detect KRAS mutations. This 
technique has the advantage of being relatively cheap; 
it is a reliable assay with good clinical applicability and 
has a well-defined track record [27]. Furthermore it allows 
the detection of all potential variations, including base 
substitutions, insertions and deletions. Nevertheless the 
biggest disadvantage of Sanger sequencing is its relatively 
low sensitivity. This technique is rarely sensitive to mutant 
allele frequencies of less than 10%, which correspond to 
the threshold of 20% of tumor cells heterozygous for a 
mutation [28]; it also requires a large amount of mutated 
DNA relative to the normal DNA present in the sample. 
Therefore in this case it is fundamental to carefully review 
the material to ensure high tumor content. Nonetheless, 
Sanger sequencing is still a useful technique for RAS 
mutation testing, and most laboratories use Sanger 
sequencing followed by pyrosequencing. This technique 
is becoming more commonly used because of its high 
analytical sensitivity, being able to detect less than 5% of 
a specific mutation in a background of wild type DNA.
Real-time PCR has been suggested as a reliable, 
feasible and low time-consuming method for RAS 
mutation testing. In addition the technique shows small 
intra- and inter-lot deviations and a good concordance 
among the different real- time PCR systems [29].
Real-time PCR methods are mainly based on two 
principles: melt-curve and allele-specific PCR analysis. 
The former allows obtainment of a quick screening of the 
possible genetic variants present in the samples. The melt-
curve analysis is based on the use of fluorescent probes 
complementary to the target amplicon and it evaluates the 
differences in the melting temperature needed to dissociate 
probe from target [30]. Differences in melting temperature 
are detected based on the loss of fluorescence as a function 
of increasing temperature (Figure 1).
Conversely, allele-specific PCR allows the 
identification of a specific mutation. It is based on the 
use of oligonucleotide primers that specifically amplify 
mutant versus wild-type sequences through the differential 
binding and extension of the primer sequences to the 
target template. A particular application of allele-specific 
PCR is the so-called CAST-PCR (Competitive Allele-
Specific TaqMan PCR). Each mutant allele assay detects 
specific or multiple mutant alleles and it is made up of: 
an allele-specific primer that detects the mutant allele; 
an oligonucleotide blocker that suppresses the wild type 
allele; a locus specific primer; and a locus specific TaqMan 
probe. This peculiar assay design allows the exquisite 
amplification of the mutant allele thus increasing the 
Table 1: List of the main techniques used for detecting gene mutations
METHOD SENSITIVITY ADVANTAGE DISADVANTAGELow High
Sanger Sequencing X
Ability to identify all mutations (also 
rare and unknown)
Low costs
It requires a large amount of 
mutated DNA relative to the wild-
type DNA
Carefully review the material to 
ensure high tumor content
Low sensitivity, 20%
High time-consuming process
Pyrosequencing X
It detects less than 5% of a specific 
mutation in a background of wild type 
DNA
It requires low amount of starting 
material
Low-time consuming process (results 
within 4 hours)
High costs
Needs of dedicated instrument, 
reagents and plastics
Problems in results interpretation
Melt-curve X
Fast screening methods for all 
mutations
Low-time consuming process
Low costs
Problems in results interpretation
Carefully review the material to 
ensure high tumor content
In case of suspected mutations 
further analysis are required to 
identify the variant
Competitive Allele-
Specific TaqMan PCR 
(CAST-PCR)
X
It detects as low as 0.1% - 1% mutated 
DNA in a background wild-type DNA
Low-time consuming process (results 
within 3 hours)
Only known mutations can be 
detected, rare or unknown variants 
may be missed
Amplification 
Refractory Mutation 
System (ARMS)
X
Some commercial kits are CE-marked
It detects 1% of a specific mutation in 
a background of wild type DNA
High costs
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sensitivity of the technique. 
Due to the differences in terms of performance 
between the various techniques, it may be recommended 
to combine different assays in order to provide the best 
means to assess clinical samples, particularly those that 
have low tumor content or from which DNA quality may 
not be optimal (Figure 2, Table 1).
Nowadays there is also a series of kits developed 
by in vitro diagnostic (IVD) manufacturers both for 
research purposes and for use in clinical diagnostics. 
For instance the TheraScreen® assay (DxS, Manchester, 
UK), based on the amplification refractory mutation 
system (ARMS) and Scorpion probes, is a CE-marked 
kit that allows the detection and qualitative assessment of 
KRAS gene mutations. Interestingly, the Food and Drug 
Administration (FDA) has approved the TheraScreen® 
KRAS RGQ PCR Kit (Qiagen, Manchester, UK) to be 
applied as a companion diagnostic test for Cetuximab 
(Erbitux). This kit uses the Scorpions® and ARMS® 
technologies and allows the detection of six mutations 
in codon 12 and one in codon 13 of KRAS [31, 32]. 
Nevertheless the TheraScreen® kit does not detect 
mutations in codon 61 of KRAS.
CLINICAL APPLICATIONS OF RAS-
RELATED PRIMARY RESISTANCE
Initial assessment of RAS mutational status, known 
as extended assessment exons, is the key to be able to 
define the best possible treatment for each mCRC patient. 
In particular, it aids in making the right choice of first-line 
chemotherapy regimen, since the presence of a possible 
mutation allows identification of a group of patients who 
would not obtain any benefit from the use of an anti-EGFR 
monoclonal antibody (moAb), cetuximab or panitumumab 
Figure 2: Proposed flow-chart of RAS analysis with the combination of different techniques. After the diagnosis of mCRC, 
firstly KRAS exon 2 (codon12-13) can be tested through allele-specific Real-Time PCR. This has a strong rationale since the majority of 
RAS mutations fall into these codons. When a mutation is detected the patient is subjected to standard chemotherapy (CT). If no mutations 
are detected it is requested to proceed with the analysis of KRAS exon3-4 and NRAS exon2-3-4 (all-RAS) through Sanger sequencing. 
The results from this analysis may be: RAS mutated (standard CT); RAS wild type (target treatment), equivocal results. In the last case it 
is advisable to proceed with pyrosequencing.
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[2, 13, 33, 34].
This is to be considered as a fundamental step that 
will affect subsequent lines of treatment and, ultimately, 
progression free survival (PFS) and overall survival 
(OS) of our patients. Of note, the need to obtain a rapid 
reduction of the tumor mass represents a key point that 
influences the choice of chemotherapy regimen. For these 
reasons, clinical research through the study of molecular 
genetics has produced numerous efforts in search of 
predictors of response to various treatments. To date, 
studies have produced evidence sufficient only as regards 
RAS mutations, initially regarding codons 12 and 13 of 
exon 2 of the KRAS gene. Regarding the G13D mutation, 
16% of KRAS mutations, there are however conflicting 
data [35, 36].
More recently the retrospective analysis of the 
prospective phase III PRIME study, which randomized 
KRAS wild type mCRC patients to receive first line 
FOLFOX + panitumumab vs FOLFOX, demonstrated the 
negative predictive value of mutations in exons 3 and 4 
of KRAS and 2, 3, 4 of NRAS. Indeed, in KRAS mutant 
patients the addition of panitumumab to FOLFOX seems 
to have a detrimental effect on PFS (HR = 1:31; 95% CI: 
1.07-1.60) and OS (HR = 1:21; 95% CI: 1:01 to 1:45). 
Conversely, median OS was 25.8 mo vs. 20.2 mo (HR = 
0.77; 95% CI: 0.64-0.94, P = 0.009) in all RAS wild-type 
populations in favour of the combination of panitumumab 
and FOLFOX [15, 37].
Similar results were obtained from the retrospective 
analysis including extended RAS evaluation carried 
out on phase III CRYSTAL and phase II OPUS studies, 
which randomized patients receiving first-line cetuximab 
in combination with FOLFIRI or FOLFOX respectively. 
In the CRYSTAL study no benefit was observed for the 
experimental arm (FOLFIRI + Cetuximab) compared to 
FOLFIRI alone in terms of RR, PFS and OS in the RAS 
mutant subgroup, while the same analysis on all RAS wild 
type patients showed an increase of 27.7% in response rate 
(RR), an increase of about 3.0 months in median PFS, and 
an increase of 8.2 months in OS [38, 39].
In the OPUS study, patients with any RAS mutation 
(KRAS exon 2 + new RAS) received no benefit from 
the addition of cetuximab to FOLFOX4; in some cases, 
the addition of cetuximab showed a statistically non-
significant trend to a worse outcome (ORR in RAS-mut 
patients to FOLFOX4 + cetuximab 37% and to FOLFOX4 
alone 51%; P = .087). No statistically significant 
differences in median overall survival were observed 
in patients with KRAS-WT or RAS-mut tumors when 
cetuximab was added to FOLFOX4 [40].
The results of these first-line studies (CRYSTAL, 
PRIME and OPUS), comprising the extended panel of 
RAS mutations, have also demonstrated with greater 
conviction the effectiveness of the addition of anti-
EGFR moAbs to, a standard chemotherapy regimen in 
terms of PFS (11.4, 12.0, 10.1 vs. 8.4, 5.8, 7.9 months, 
respectively) and in terms of OS (28.4, 19.8, 26.0 vs 20.2, 
17.8, 20.2 months, respectively). The unique role as a 
negative predictor of response to anti-EGFR molecules 
of RAS mutations has been further strengthened by the 
final results of the TRIBE study, a prospective phase III 
trial which randomly assigned patients, never treated for 
advanced disease, to receive FOLFIRI + Bevacizumab 
or FOLFOXIRI + Bevacizumab. The subgroup analysis 
extended to not frequent RAS mutations showed in RAS 
and BRAF wild-type patients a trend in favor of the triplet-
based regimen in terms of PFS (13.3 vs 11.3 months) and 
in terms of OS (41.7 vs 34.4 months). Of note, in the RAS 
mutant population the results were very similar (12.0 
PFS, OS 28.6 months) between the two treatment arms, 
confirming the negative predictive role of RAS mutations. 
On the contrary, these results seem to confirm the data on 
the role of negative prognostic BRAF mutations (BRAF 
wild type and mut OS 41.7 and 19.1 months, respectively, 
in the arm containing the triplet) [41, 42].
In spite of the confirmed negative prognostic role 
of BRAF mutations (8% of RAS wild-type), their role as 
predictive of response to an anti-EGFR based regimen has 
not yet been defined because of discordant outcomes from 
frontline studies (CRYSTAL, PRIME and OPUS) and 
other studies.
Expectations were high regarding the results 
from two studies that compared head to head a first-line 
treatment consisting of a chemotherapeutic doublet with 
the addition of anti-EGFR or anti-VEGF mAbs. The 
FIRE-3study, a phase III trial, compared FOLFIRI + 
bevacizumab to FOLFIRI + cetuximab in a population of 
KRAS exon 2 wild-type patients. In spite of a difference 
in terms of RR, the primary endpoint of the study 
was not highlighted in the primary analysis, and the 
retrospective analysis extended to rare RAS mutations 
showed substantial differences in terms of RR (72% vs 
56.1%) in the cetuximab arm (p = 0.003). As regards 
early tumor shrinkage (ETS), PFS in patients with ETS 
in the cetuximab arm was 9.7 months vs 5.8 months in 
patients with no-ETS. In the bevacizumab arm the PFS in 
ETS patients was 11.7 months vs 8.3 months in non-ETS 
patients, and finally deepness of response (DpR) correlated 
significantly with OS and PFS (p = 0.0003 in KRAS exon 
2 wild-type patients and p < 0.0001 in the final RAS wild 
type population).
These important results were partially confirmed 
by the data from the second phase III study, the CALGB 
80405 trial, comparing patients for the KRAS wild-
type exon 2 subjected to a combination regimen at the 
discretion of the investigator (FOLFOX or FOLFIRI) 
with the addition of an anti EGFR or anti-VEGF 
moAbs. Also in this case, although the retrospective 
analysis extended to rare mutations of RAS, there was 
no significant difference between the two monoclonal 
antibodies in terms of OS (32.0 vs 31.2). These data 
suggest that both these are alternative treatments in this 
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setting. The analysis of RR emphasized a difference 
in RR in favor of regimens containing the anti EGFR 
(68.6% vs 53.6%) [43, 44]. Finally, the randomized phase 
II PEAK trial, which compared FOLFOX+Panitumumab 
with FOLFOX+Bevacizumab in wild-type KRAS exon 2 
untreated patients, showed an improvement of PFS and 
a trend towards improved OS in panitumumab-treated 
patients. However these results are limited by the small 
sample size [45, 46].
A recent meta-analysis evaluated data from nine 
trials as regards KRAS exon 2 wild-type tumors and other 
RAS mutations (in exons 3 and 4 of KRAS and exons 
2, 3 and 4 of NRAS) as predictive factors of primary 
resistance. By pooled HRs no PFS or OS benefits were 
observed when anti-EGFR moAbs were delivered to 
patients with any RAS mutation. As a consequence all 
these RAS mutations are deemed as negative predictive 
factors [16].
In conclusion, the outcomes of all these analyses, 
which include rare RAS mutations, do not give oncologists 
a great deal of information on what is the best combination 
regimen for mCRC patients. In the absence of significant 
advantages in terms of OS, these new data regarding the 
response rate associated with the initial clinical evaluation 
of the patient may allow the construction of a treatment 
algorithm to guide the choice of a combination regimen 
in all RAS wild-type patients, with the addition of an anti-
EGFR moAb in case of highly symptomatic patients who 
require a rapid reduction in tumor volume or, alternatively, 
of a regimen containing an anti-VEGF moAb, which also 
becomes the first choice of treatment in RAS mutated 
patients or carriers of a BRAF mutation [34].
THE IMPACT OF OTHER PREDICTIVE 
BIOMARKERS
As reported above, RAS mutations represent the 
most important predictive biomarker of resistance to anti-
EGFR therapy in mCRC, and the only one approved for 
clinical use. However mutant RAS only accounts for about 
50% of non-responders to anti-EGFR therapy. Therefore 
additional predictive biomarkers are needed in order to 
better select those patients who may really gain benefit 
from anti-EGFR treatments, and sparing others from a 
futile treatment and related toxicities.
BRAF mutations
BRAF is a proto-oncogene localized on 
chromosome 7 (7q34), encoding a serine-threonine 
protein kinase, and is a member of the RAF subfamily 
(together with the ARAF and RAF1 protein) which 
directly interacts with RAS. Mutations of B-RAF are 
reported in approximately 3-15% of mCRC and are 
mutually exclusive with RAS mutations [47, 48]. As in 
other malignancies, such as melanoma or NSCLC, the 
most common reported mutation is V600E, accounting 
for about 80% of all BRAF mutations in mCRC [49]. 
It consists of a substitution of valine with glutamate 
at codon 600 on exon 15, resulting in a constitutive 
activation of the RAF kinase and of the RAF–MEK–
ERK downstream signaling pathway, responsible for both 
cancer cell proliferation and survival, independently of 
the EGFR blockade [50, 51]. Much evidence suggests 
that BRAF mutation is a strong negative prognostic factor 
in mCRC patients, regardless of treatments received 
[48, 52-58]. Although two meta-analyses have recently 
shown a negative predictive value of BRAF mutations 
for anti-EGFR treatment in mCRC [59, 60], their 
potential application for clinical practice is still debated. 
Retrospective studies have shown that the occurrence of 
a BRAF mutation is significantly associated with inferior 
outcomes in RAS WT, mCRC patients receiving anti-
EGFR therapy as second or subsequent lines of treatment. 
Even if these data were not confirmed in the updated 
analysis of the study of Peeters et al. [61], BRAF mutation 
seems to be a negative predictor for anti-EGFR moAb 
treatment in the chemo-refractory setting [48, 62, 63]. 
On the other hand, unlike RAS mutations, the predictive 
value of B-RAF mutations in the first-line setting has not 
been fully demonstrated. Some retrospective studies have 
suggested that the BRAF mutation confers resistance to 
anti-EGFR therapy [64, 65], while a retrospective analysis 
of the COIN trial did not support the negative predictive 
role of the BRAF V600E mutation [66]. A pooled analysis 
including both CRYSTAL and OPUS trials retrospectively 
investigated the efficacy of Cetuximab plus chemotherapy 
in KRAS wild-type mCRC patients, according to BRAF 
mutational status. The results of such analyses have shown 
a significant benefit associated with the addition of anti-
EGFR to chemotherapy in the KRAS/BRAF wild-type 
population, while the improvements in both PFS and OS 
among the 70 KRAS wild-type / BRAF mutated patients 
did not reach statistical significance, likely because of the 
small size of the B-RAF mutant population included in 
both the studies. Furthermore, B-RAF mutated patients 
treated with chemotherapy alone also reported worse 
outcomes compared with the B-RAF WT population, 
suggesting a predominant negative prognostic value 
of the B-RAF mutation [67]. The subgroup analysis of 
BRAF mutations in both the phase III PRIME study and 
FIRE-3 study, respectively comparing panitumumab plus 
FOLFOX versus FOLFOX and Cetuximab plus FOLFIRI 
vs Bevacizumab plus FOLFIRI as first-line treatment 
for mCRC, also did not confirm the predictive value of 
B-RAF mutations in this setting of patients [15, 68].
Recently, a prospective study evaluating the 
predictive significance of the BRAFV600E mutation 
in KRAS wild-type mCRC patients, in treatment with 
anti-EGFR therapies, showed that patients with BRAF 
mutated tumors have lower PFS and OS compared to 
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patients with BRAF WT. Such survival differences were 
not statistically different in the first line-setting, while they 
reached a significant relevance in second or subsequent 
lines of treatment, according to previous evidence [69]. 
To date, the available data are insufficient to support the 
use of BRAF mutations as clinical predictive biomarkers 
for the upfront selection of mCRC patients, candidate 
to anti-EGFR therapy, and their low prevalence further 
limits their potential utility in clinical practice. However, 
another study presented at the 2014 ASCO meeting 
reported BRAF mutations in 11% of 37 mCRC patients 
with acquired resistance to cetuximab-based treatment, 
suggesting also a potential role in the development 
of resistance during anti-EGFR therapy [70]. BRAF 
mutations have also been detected noninvasively by ct-
DNA analysis at the time of progression in mCRC patients 
who had previously responded to anti-EGFR therapy, 
supporting the idea that such a mutation alone, or together 
with other molecular alterations, such as RAS mutations, 
may sustain the emergence of acquired resistance during 
anti-EGFR treatments [17, 71].
PIK3CA mutations
PIK3CA is a proto-oncogene localized on 
chromosome 3 (3q26.3), encoding the catalytic 
(p110) subunit of the class IA phosphatidylinositol3-
kinases (PI3K). It is an intracellular lipidic kinase, 
recruited by the EGFR tyrosine-kinase domain, able to 
convert phosphatidylinositol- bisphosphate (PIP2) to 
phosphatidylinositol-triphosphate (PIP3), and ultimately 
responsible for the phosphorylation of AKT and the 
activation of the downstream AKT-mTOR signaling 
pathway, mediating both cell proliferation and survival 
[72]. Somatic mutations of the PIK3CA gene are reported 
in about 15-20% of CRC, and may co-exist with both 
RAS and BRAF mutations [62, 73]. More than 80% 
of PIK3CA mutations map to the exon 9 (60-65% of 
mutations) and exon 20 (20-25% of mutations) hot-spots 
[62, 74], leading to the constitutive activation of the PI3K 
catalytic (p110) subunit and the downstream AKT/mTOR 
signaling pathway, independently of EGFR blocking. 
Some retrospective studies have investigated the potential 
role of PIK3CA mutations as a predictor of resistance to 
anti-EGFR treatments in mCRC patients, with conflicting 
results. Sartore-Bianchi et al. showed that KRAS wild-
type mCRC patients under anti-EGFR treatment whose 
tumors harbored PIK3CA mutations had significantly 
lower RR and PFS compared to a PIK3CA WT population. 
Moreover all responders were found to be PIK3CA wild-
type [75]. In contrast, Prenen et al. did not support a 
significant difference in both RR and survival outcomes 
between PIK3CA mutated and WT mCRC patients treated 
with Cetuximab as monotherapy or in combination with 
irinotecan, in second or subsequent lines of treatment [74]. 
Finally, a large retrospective European analysis, involving 
708 mCRC chemo-refractory patients, under anti-EGFR-
treatment, showed that exon 20, but not exon 9, mutations 
of the PIK3CA gene were significantly associated with 
lower RR, PFS, and OS, compared to a WT population. 
Moreover exon 20 mutations were mutually exclusive 
with KRAS mutations, whereas exon 9 mutations were 
more often concomitant with KRAS mutated than KRAS 
wild-type CRC [62]. Such evidence allows to explain 
also the conflicting results of the two aforementioned 
studies, which were both characterized by a significant 
heterogeneity of the distribution of mutations in the two 
different exons in the included cohorts. Indeed the study 
by Sartore-Bianchi on PIK3CA mutated patients included 
respectively 73% exon 20 and 27% exon 9 mutations, 
compared to 13% and 78% exon 20 and 9 mutations 
respectively, in the study by Prenen et al. Overall these 
data suggest that PIK3CA exon 20 mutations may play a 
role as predictive biomarkers of resistance to anti-EGFR 
therapy in KRAS WT mCRC patients, as confirmed in 
two recent meta-analysis [60, 76]. However, because of 
its low frequency, further prospective studies are needed 
to support the clinical utility of PIK3CA analysis in the 
selection of those patients candidate to anti-EGFR therapy.
PTEN loss
PTEN is a tumour suppressor gene, localized on 
chromosome 10 (10q23.3), encoding a phosphatase 
protein, which negatively regulates the PI3K-AKT 
signaling pathway. Loss of the PTEN protein through 
both genetic and epigenetic mechanisms is reported in 
about 20-40% of mCRC [77], resulting in a constitutive 
hyperactivation of the PI3K-AKT signaling pathway, 
responsible for tumor cell proliferation and survival 
[78]. Some studies have retrospectively investigated the 
predictive value of PTEN loss in mCRC patients under 
treatment with anti-EGFR therapy, reporting conflicting 
and inconclusive results. Loupakis et al. have shown that 
PTEN loss, detected by the IHC method, was associated 
with lower responses, compared with PTEN positive 
tumours of 102 chemo-refractory mCRC patients, 
treated with cetuximab + irinotecan. However such 
differences were significant in the metastatic lesions, but 
not in the primary tumours, suggesting that, unlike RAS 
mutations, PTEN expression may change over time [79]. 
Furthermore the analysis of survival outcomes, according 
to PTEN expression in metastatic lesions, has also shown 
a significant difference in PFS, in favor of the PTEN 
positive cohort, while a significant improvement in OS was 
observed only in PTEN positive, RAS wild-type patients. 
Another study by Sartore-Bianchi confirmed a significant 
association between PTEN loss and lack of benefit from 
anti-EGFR therapy in mCRC patients, both in terms of RR 
and PFS/OS. Finally a retrospective French study did not 
show any differences in terms of RR and PFS, according 
to PTEN expression, in a cohort of chemo-refractory, RAS 
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wild-type mCRC patients [64]. However, a significantly 
lower OS was reported in the subgroup of PTEN negative 
patients, compared to those with PTEN positive tumors, 
suggesting a potential negative prognostic role of PTEN 
loss. Even if a recent meta-analysis confirmed that PTEN 
loss was significantly associated with lack of benefit to 
anti-EGFR therapy in RAS wild-type mCRC patients, the 
authors concluded that the predictive power of B-RAF 
and PIK3CA mutations were stronger than PTEN loss, 
not excluding that some patients with a single alteration 
could still gain benefit from anti-EGFR treatment [60]. 
Therefore, larger and prospective clinical trials, including 
a standardized method to detect PTEN expression, are 
required to establish its potential role as a predictive 
biomarker in RAS wild-type mCRC patients candidate to 
anti-EGFR-therapy.
AREG and EREG expression
The expression of the EGFR ligands amphiregulin 
(AREG) and epiregulin (EREG) has been suggested as 
a possible mechanism that could influence the response 
to the anti-EGFR moAbs, cetuximab and panitumumab, 
in mCRC patients. A high concentration of these ligands 
is supposed to be related with a more aggressive tumor 
growth, but the rates of KRAS mutations are lower in 
tumors overexpressing EGFR ligands [80]. A retrospective 
study evaluated AREG and EREG expression in 220 
mCRC patients enrolled in clinical trials (EVEREST, 
BOND, SALVAGE, and BABEL) [11, 81, 82]. The 
analyses were performed on formalin-fixed paraffin-
embedded primary tumor samples through RNA 
extraction and real time PCR. High levels of EREG have 
been associated with a higher probability of objective 
responses and the majority of patients with high levels of 
EREG belonged to the group with complete and partial 
responses. Moreover, high levels of EREG expression 
in KRAS wild-type patients treated with irinotecan and 
cetuximab conferred a benefit in PFS in comparison with 
those with low ligand expression whose behavior was 
similar to patients with KRAS mutant tumors [83]. A 
recent study presented by J.F. Selingman et al. at the 2014 
ASCO annual meeting evaluated the correlation between 
the expression levels of both AREG and EREG mRNAs 
in 323 RAS wild-type patients treated with irinotecan 
as second line therapy, with or without Panitumumab 
and enrolled in the randomized PICCOLO trial [63]. 
The results showed that the high level of expression of 
the mRNAs of both ligands had a predictive value for 
the RAS wild-type population demonstrating a benefit 
in PFS for those patients treated with irinotecan and 
Panitumumab versus irinotecan alone (mPFS 8.3 vs 4.4 
months; HR: 0.62; 95% CI 0.49 – 0.78; p< .001), while 
for RAS wild-type patients with low AREG and EREG 
expression, no benefit was obtained. No prognostic 
significance was found in terms of PFS or OS [84]. These 
data indicate that the evaluation of the expression levels of 
EGFR ligands could be a promising path towards a more 
accurate selection of RAS wild-type patients to treat with 
anti-EGFR drugs, but more consistent evidence is needed 
to make this hypothesis part of daily practice.
HER-2 amplification
HER2 is a receptor that belongs to the ErbB family 
and whose activation does not require the presence of a 
ligand. Indeed it depends on the heterodimerization of 
HER2 with other similar receptors of the family. A high 
level of activation of HER2 can also be promoted by 
gene amplification and subsequent HER2 overexpression 
[85]. Preclinical evidence suggested a possible role of 
the heterodimers of EGFR with other members of the 
HER family, such as HER2 and HER3, in affecting the 
efficacy of anti-EGFR based therapies. Two studies have 
demonstrated a correlation between the amplification of 
HER2 and the acquired resistance of mCRC to cetuximab 
therapy (see below) [86, 87]. Recent retrospective 
data confirm that the analysis by FISH of the HER2 
amplification status could represent a promising way to 
better identify subgroups of mCRC patients for treatment 
with anti-EGFR drugs. Martin et al. evaluated HER2 
gene status in 170 KRAS wild-type mCRC patients 
treated with cetuximab or panitumumab identifying three 
profiles: a) patients with no or slight HER2 amplification 
(35%); b) patients with HER2 amplification in minor 
clones or with increased HER2 gene copy number due to 
polysomy (HER2-CNG) (61%); c) patients with HER2 
amplification in all cells. The worst outcome was seen 
in the group of patients with amplification in all cells, 
while intermediate outcomes were seen for patients with 
no amplification. Interestingly the best outcomes were 
seen in the group of patients with amplification in minor 
clones or polysomy. Authors explain these different 
results supposing that tumors in the group with HER2 
amplification in a minority of the cells or with HER2 
polysomy may have a different pathogenesis linked to a 
general chromosome instability. In the group with HER2 
amplification in all cells however, HER2 activation can 
bypass the blockade of EGFR mediated by panitumumab 
and cetuximab, inducing a strong resistance to these 
moAbs but placing the biological basis for anti-HER2 
therapy in this group of patients. The lack of efficacy of 
anti-EGFR treatment for the patients with no amplification 
of HER2 has been related to kariotypic heterogeneity [88]. 
In a recently published work, Cushman et al. investigated 
the expression of EGFR axis-related genes, analysing 
103 tumor samples from the CALGB 80203 trial to 
find prognostic or predictive markers for patients with 
mCRC and treated with cetuximab and chemotherapy as 
first line treatment: the expression levels of 14 EGFR-
related genes were correlated with clinical outcomes 
(OS and PFS). Surprisingly, high mRNA levels of 
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HER2 (HR=0.64) and epiregulin (HR=0.89) showed a 
prognostic association with longer PFS for all patients 
while a positive trend toward better OS was found for the 
same genes in the overall population [89, 90]. Although 
these data are preliminary and partially conflicting, they 
confirm a potential role of HER2 overexpression in 
guiding the response of tumors to anti-EGFR treatments. 
At the moment, however, such evidence does not allow 
definitive conclusions and prospective studies are needed 
for this purpose.
PRECLINICAL AND TRANSLATIONAL 
FINDINGS ABOUT RAS-RELATED 
ACQUIRED RESISTANCE
Since anti-EGFR moAbs were introduced into 
clinical practice for the treatment of mCRC, primary 
resistance has been studied to select those patients 
with higher probability of benefit. Concomitantly the 
mechanisms of acquired resistance have been investigated 
as cancer progression steadily develops during treatment 
by these targeted agents.
Among the first investigations on acquired resistance 
to cetuximab, Wheeler et al. examined the activity of 42 
receptor tyrosine kinases (RTK) in cetuximab-resistant cell 
lines. They found high activity of EGFR, HER2, HER3 
and cMET. This phenomenon seems to be mediated by an 
overexpression of EGFR as a consequence of disregulated 
internalization and degradation of EGFR, which 
subsequently heterodimerizes with the other RTKs and 
transactivates them. However HER3 activation appears to 
be more crucial than the other RTKs in inducing acquired 
resistance to cetuximab [91].
Cetuximab-resistant clones have a marked 
nuclear expression of EGFR. This EGFR in the nuclear 
compartment works as a transcription factor for cyclin D1, 
iNOS, B-myb and Aurora kinase A, and phosphorylates 
and stabilizes PCNA. The accumulation of EGFR in the 
nucleus is favoured by several EGFR ligands, such as 
EGF, HB-EGF, AR and β-cellulin. Src family kinase (SFK) 
is a mediator of EGFR translocation, as its inhibition by 
dasatinib may restore sensitivity to cetuximab [92].
Further in vitro studies on anti-EGFR-resistant cells 
showed higher levels of phosphorylated EGFR, MAPK, 
AKT and STAT3, which were associated with reduced 
apoptosis [93]. Some preclinical studies on resistant cells 
in xenograft models discovered a role of angiogenesis 
dysregulation. Angiogenesis is an important determinant of 
tumor progression, therefore new therapeutic approaches 
are necessary to control angiogenic spread [94]. These 
angiogenic mechanisms involved in resistance to anti-
EGFR agents include increased expression of VEGF and 
other VEGFR-1 ligands. Despite this intriguing preclinical 
evidence, phase III randomized trials did not find benefit 
from combined inhibition of EGFR and VEGF pathways 
[95-98].
The role of KRAS mutations in acquired resistance 
to anti-EGFR moAbs was first reported by Bouchahda 
et al. [99]. These authors published a case report of a 
mCRC patient with a KRAS wild-type primary tumor 
and synchronous metastases evaluated before beginning 
treatment with cetuximab. However, after initial 
significant tumor shrinkage on cetuximab and subsequent 
progression, a segment hepatectomy allowed to evaluate 
the mutational status of a metachronous liver metastasis. 
They detected both codon 12 and 13 KRAS mutations. 
These mutations are known to be very early events in 
colorectal carcinogenesis. This observation is corroborated 
by the findings of high concordance, about 90%, in 
primary tumors and in metastases [79, 100-102].
For this reason it was argued that the onset of 
new KRAS mutations could be a consequence of 
clonal selection of cells early mutated in the KRAS 
gene. This selection is the effect of selective pressure 
by anti-EGFR moAbs. An alternative explanation is 
represented by the development of novel spontaneous 
mutations, maybe favoured by cytotoxic therapy. The 
intratumor heterogeneity of the cancer cell population is 
the better background for the genesis of potential drug-
resistant metastatic clones and it may also explain why 
the mutations in these clones could be missed in DNA 
detection in tumor samples[103, 104].
Further genomic alterations have been implicated 
in acquired resistance to anti-EGFR moAbs in preclinical 
studies [105]. Aberrant ERBB2 signalling, by ERBB2 
amplification or heregulin production, seems to be 
responsible for both intrinsic and acquired resistance in 
cetuximab-treated mCRC patients. This ERBB2 signalling 
impairment represents the activation of a bypass signalling 
pathway. The aberrant activation of the ERBB2 gene leads 
to persistent ERK1/2 signalling during treatment with 
cetuximab, and subsequently the development of acquired 
resistance to this agent. Of note, breast cancer cells 
treated with the anti-ERBB2 moAb trastuzumab have an 
activation of EGFR signalling as a mechanism of acquired 
resistance. However this phenomenon is not observed for 
tyrosine kinase inhibitors (TKI), which can inhibit both 
EGFR and ERBB2 at clinically achievable concentrations 
[86, 87, 106, 107].
The amplification of other genes was also observed 
as a mechanism of de novo and acquired resistance. The 
amplification of the KRAS gene is mutually exclusive 
with KRAS or BRAF mutations. It induces overexpression 
of the KRAS wild-type protein with changes of gene 
expression similar to those caused by mutant KRAS 
variants. However this genomic alteration was reported 
in a small proportion of patients treated with anti-EGFR 
moAbs, around 4%. Besides, KRAS amplification has 
been shown to have a deterministic effect on anti-EGFR 
resistance in in vitro studies. Indeed its occurrence in 
sensitive cells favours resistance and its silencing restores 
sensitivity [108].
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Similarly MET amplification was found at high 
levels in patients who progressed during treatment 
with anti-EGFR therapy. In the same study other gene 
copy number variations were not found, while the other 
resistance-inducing oncogenes remained non-mutated. 
Interestingly MET amplification can be detected in 
circulating DNA over time. MET amplification was 
found at low levels in tumor tissues before treatment. 
As a consequence it could represent theoretically a 
mechanism for de novo resistance. But the small amount 
of MET-amplified cells can be expanded by the selective 
pressure of anti-EGFR moAbs and they can induce 
acquired resistance, as they become the leading tumor 
cell population. This phenomenon has highly relevant 
therapeutic implications, since MET is an actionable 
target and MET inhibitors, such as crizotinib, are under 
investigation [109].
A missense mutation in the EGFR extracellular 
domain (S492R) was detected by sequencing analysis. 
This mutation hinders cetuximab binding and it resulted 
in the retention of EGFR activity during exposure to 
cetuximab but not panitumumab. It was not detected in 
tumor samples from untreated mCRC patients [110, 111].
A cross talk between EGFR and MET has been 
shown. EGFR immunoprecipitated together with MET 
in cetuximab-resistant colorectal cancer cells, and this 
interaction was also observed in parental cells by TGFα 
stimulation. This interaction between EGFR and MET 
induces the activation of MET as a consequence of a 
stimulation with ligands binding both receptors and has a 
synergistic effect on the downstream effector of respective 
pathways. Moreover TGFα plasma levels were higher 
during treatment with cetuximab, even though they do 
not influence tumor response. Accordingly, high TGFα 
mRNA levels were significantly increased in patients 
progressing during cetuximab treatment. Therefore the 
overexpression of TGFα induces the interaction of EGFR 
and MET, with subsequent phosphorylation and activation 
of MET and its effectors. This mechanism could explain 
the development of resistance to anti-EGFR agents and 
it suggests to overcome this resistance by the combined 
inhibition of EGFR and MET. Conversely high expression 
levels of AREG and EREG ligands are related to a better 
response to cetuximab [112-114].
More recently the paracrine secretion of EGFR 
ligands has been implicated in the acquired resistance to 
cetuximab. Some authors have suggested a “paracrine 
in trans protection of sensitive cells by their mutated 
derivatives”. According to this explanation, sensitive RAS 
wild-type cells and resistant RAS-mutated cells cooperate 
to develop the acquired resistance [115].
The downstream molecules in the EGFR pathways 
have also been studied to explain the mechanisms of 
acquired resistance to anti-EGFR moAbs. In addition to 
the mutations in the genes involved in the same pathway 
and the pathways cross-talking (KRAS, BRAF, NRAS, 
MET and HER2), a sustained activation of MEK and 
ERK in terms of constitutive phosphorylation has been 
implicated in acquired resistance. However the blockade 
of MEK is not sufficient to inhibit the proliferation of 
resistant cells. Only the concomitant blockade of EGFR 
and MEK achieves a reversion of secondary resistance. 
This evidence has been explained by the transient ERK 
inactivation upon MEK inhibition, which leads to the 
phosphorylation of EGFR. However a mechanism of this 
EGFR feedback activation has not yet been found [71].
Accordingly, in another in vitro study the acquired 
resistance was defined by the lack of blockade of MAPK 
and AKT activation in spite of EGFR inhibition. In this 
study the combined treatment with cetuximab and a 
MEK1/2 inhibitor has a synergistic effect, as can be 
verified by the inhibition of activated pAKT and pMAPK. 
This inhibition leads to cell apoptosis as confirmed by 
increased levels of cleaved PARP and caspase-3 activation. 
MEK1/2 silencing restores the ability of cetuximab to 
inhibit MAPK and cell proliferation [116].
All these studies led to the identification of possible 
mechanisms to explain the onset of acquired resistance 
to anti-EGFR moAbs in mCRC patients. Only a small 
amount of genes appear to confer resistance. And this 
observation is encouraging for attempting to overcome the 
resistance. The new approach of liquid biopsy by cell-free 
circulating tumor DNA allowed to monitor the appearance 
of mutations of these genes in wild-type patients [17].
As a consequence of these findings a question 
arises: how could gene mutations responsible for acquired 
resistence to anti-EGFR moAbs emerge? Some studies 
could provide an answer to this question. The study by 
Diaz et al. provided further data about gene mutations in 
circulating DNA. The authors developed a mathematical 
model which led to the conclusion that these mutations 
were present in expanded subclones prior to the initiation 
of the anti-EGFR moAbs. The results of this analysis agree 
with the in vitro study by Misale S et al., who continuously 
treated colon cancer cell lines with cetuximab leading 
to the emergence of resistant variants. The molecular 
alterations, KRAS mutations and amplification identified 
in resistant cells were also detected in a minority 
population of parental cells. These results suggest that the 
change from sensitive to resistant phenotype could derive 
from selection of pre-existing resistant clones. However 
a further experiment on sensitive cells, which were 
confirmed to be wild-type by high-sensitivity analyses, 
showed the appearance of KRAS mutation upon treatment 
with increasing concentrations of cetuximab. Therefore 
the resistance to anti-EGFR moAbs may also emerge 
by ongoing mutagenesis. Further preclinical studies are 
needed to explain these phenomena, but all these findings 
helped to propose new treatment strategies to overcome or 
prevent resistance to anti-EGFR moAbs in mCRC patients 
[26, 117, 118].
It is usually thought that anti-EGFR moAbs work by 
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avoiding the activation of EGFR pathway by its ligands. 
A significant apoptosis of tumor cells was not observed 
by Cetuximab. Tyrosine kinase inhibitors of EGFR have 
not shown efficacy in colon cancer patients yet. Some 
researchers hypothesized a role by antibody-dependent 
cellular cytotoxicity (ADCC) [119, 120]. The binding of 
the Fc region of a moAb to a Fc receptor expressed with 
different patterns by cells of the innate immune system, 
namely monocytes, macrophages, granulocytes and 
natural killer cells (NK). Cetuximab was able to mediate 
NK-dependent ADCC in vitro, since NK cells are the main 
mediators of the ADCC-dependent therapeutic effects by 
cetuximab [121]. Instead, panitumumab is less effective 
in inducing NK-dependent ADCC, maybe because IgG2 
immunoglobulins have a reduced avidity for Fc receptor 
in comparison with IgG1. It has been supposed that the 
entity of ADCC in cancer patients treated with cetuximab 
may help to predict tumor response. In colorectal cancer 
cells KRAS mutations may interfere with ADCC activity. 
Besides cancer patients may experience a lower induction 
of ADCC by cetuximab in comparison with healthy 
subjects as related to potential immunosuppression in 
cancer patients [122]. Myeloid-derived suppressor cells 
and other inflammatory cells could explain this limitation 
of cetuximab-related ADCC.
CONCLUSIONS
The introduction of anti-EGFR moAbs in 
combination with chemotherapy regimens for mCRC 
patients improved OS and quality of life. Nowadays 
these agents are the standard treatment for these patients. 
However several clinical studies have highlighted the 
predictive role of gene alterations involved in the EGFR 
pathway. For each mCRC patient the analysis of these 
biomarkers in tissue biopsy is mandatory to decide the 
proper treatment. Until now many genomic alterations 
have been identified. Among these biomarkers RAS 
mutations in exon 2 and 3 are the most clearly defined 
for clinical practice. The data for the other biomarkers, 
including BRAF mutations, PIK3CA mutations, 
PTEN loss, AREG and EREG expression and HER-
2 amplification, are still inconclusive or incomplete. 
Further findings are emerging regarding the role of these 
biomarkers as predictive for acquired resistance. Liquid 
biopsy will help to identify and monitor the biomarkers 
for both primary and acquired resistance. The application 
of this new method will be granted by the validation of 
high-sensitivity techniques for the isolation and detection 
of somatic mutations in cell-free circulating tumor DNA. 
Besides, it will allow to identify various mutations at the 
same time. This opportunity will speed up the process of 
patient selection for anti-EGFR moAbs.
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